Local delivery of mithramycin restores vascular reactivity and inhibits neointimal formation in injured arteries and vascular grafts.
Arterial restenosis is responsible for the high failure rates of vascular reconstruction procedures. Local sustained drug delivery has shown promise in the prevention of restenosis. The drug release rate from mithramycin-loaded EVA matrices (0.1%) was evaluated, and their antirestenotic effect was studied in the rat carotid model and rabbit model of vascular grafts. The modulation of c-myc expression by mithramycin treatment was examined by immunohistochemistry in the rat carotid model. The proliferative response of injured rat arteries was studied by bromdeoxyuridine (BrdU) immunostaining. The impact of mithramycin treatment on vasomotor responses of the venous segments grafted into arterial circulation was studied ex vivo using vasoreactive compounds. Mithramycin was released exponentially from EVA matrices in PBS. Matrices co-formulated with PEG-4600 revealed enhanced release kinetics. The perivascular implantation of drug-loaded EVA-PEG matrices led to 50% reduction of neointimal formation, and reduced the c-myc expression and BrdU labeling in comparison to control implants. Decreased sensitivity of mithramycin-treated grafts to serotonin-induced vasoconstriction was observed. Local perivascular mithramycin treatment limits the functional alteration caused by the grafting of venous segments in high-pressure arterial environment, and potently inhibits stenosis secondary to grafting and angioplasty injury. The antirestenotic effect is associated with reduced c-myc expression and with subsequent decrease in SMC proliferation.
Fishbein
I
I
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, 91120, Jerusalem, Israel.
Brauner
R
R
Chorny
M
M
Gao
J
J
Chen
X
X
Laks
H
H
Golomb
G
G
D000818:Animals; D017536:Carotid Artery, Common / Q000187:drug effects / Q000503:physiopathology / Q000637:transplantation*; D002404:Catheterization / Q000009:adverse effects; D002478:Cells, Cultured; D016503:Drug Delivery Systems / Q000379:methods*; D006083:Graft Occlusion, Vascular / Q000473:pathology / Q000517:prevention & control*; D006131:Growth Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D007601:Jugular Veins / Q000187:drug effects / Q000503:physiopathology / Q000637:transplantation*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D008926:Plicamycin / Q000008:administration & dosage* / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013552:Swine; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology
D006131:Growth Inhibitors; D008926:Plicamycin